|
Gene: SCRG1 |
Gene summary for SCRG1 |
Gene summary. |
Gene information | Species | Human | Gene symbol | SCRG1 | Gene ID | 11341 |
Gene name | stimulator of chondrogenesis 1 | |
Gene Alias | SCRG-1 | |
Cytomap | 4q34.1 | |
Gene Type | protein-coding | GO ID | GO:0007275 | UniProtAcc | O75711 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
11341 | SCRG1 | GSM4909281 | Human | Breast | IDC | 1.71e-88 | 1.26e+00 | 0.21 |
11341 | SCRG1 | GSM4909285 | Human | Breast | IDC | 1.38e-09 | 2.65e-01 | 0.21 |
11341 | SCRG1 | GSM4909286 | Human | Breast | IDC | 3.31e-82 | 1.06e+00 | 0.1081 |
11341 | SCRG1 | GSM4909299 | Human | Breast | IDC | 2.68e-06 | 2.33e-01 | 0.035 |
11341 | SCRG1 | DCIS2 | Human | Breast | DCIS | 2.09e-24 | 2.71e-01 | 0.0085 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Breast | IDC: Invasive ductal carcinoma | |
DCIS: Ductal carcinoma in situ | ||
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | CRC | |
Stomach | GC | |
Stomach | CAG with IM | |
Stomach | CSG | |
Stomach | CAG |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SCRG1 | SNV | Missense_Mutation | novel | c.71N>T | p.Asn24Ile | p.N24I | O75711 | protein_coding | tolerated_low_confidence(0.15) | benign(0.033) | TCGA-AX-A1C9-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SCRG1 | SNV | Missense_Mutation | c.177N>A | p.Phe59Leu | p.F59L | O75711 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
SCRG1 | SNV | Missense_Mutation | rs757953805 | c.74G>A | p.Arg25His | p.R25H | O75711 | protein_coding | tolerated_low_confidence(0.13) | probably_damaging(0.999) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SCRG1 | SNV | Missense_Mutation | novel | c.239N>A | p.Pro80Gln | p.P80Q | O75711 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-05-4420-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
SCRG1 | SNV | Missense_Mutation | novel | c.179N>T | p.Trp60Leu | p.W60L | O75711 | protein_coding | deleterious(0.04) | probably_damaging(0.998) | TCGA-CN-6010-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | cisplatin | PD |
SCRG1 | SNV | Missense_Mutation | c.96A>G | p.Ile32Met | p.I32M | O75711 | protein_coding | tolerated_low_confidence(0.11) | benign(0.02) | TCGA-HJ-7597-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Chemotherapy | fluorouracil | CR |
Page: 1 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |